Moderna shares surged about 150% after Moderna and Merck reported positive Phase 3 results for a personalized mRNA treatment ...

The study also met a secondary goal of preventing cancer from spreading to different parts of the body.

The companies said their vaccine helped prevent the return and spread of melanoma in a trial that involved more than 1,000 ...

Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak ...

President Donald Trump’s announcement this week of White House aide Heidi Overton as his pick to lead the FDA gave the pharma ...

Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the ...

Just a year after RFK Jr. cut half a billion of funding for the technology, mRNA vaccines are promising individualized cancer ...

MEXC, a pioneer in 0-fee digital asset trading, has listed the MRNAON/USDT trading pair on Spot, giving users a new ...

Positive Phase 3 KEYTRUDA Results Advance Personalized Melanoma Treatment / cancer, Keytruda, Melanoma, Merck, Moderna, ...

Each patient's vaccine is built from an analysis of the mutations found in that patient's own tumour, CNN reported, rather ...

Your resource for the hottest moving stocks and news. We cover all sectors and markets giving everyday investors access to ...